The Home-Based Sleep Laboratory

INTRODUCTION

Sleep disturbances are one of the most common non-motor symptoms in Parkinson’s disease (PD), with an estimated prevalence as high as 40– 90% [1, 2]. Sleep duration, sleep fragmentation, Rapid Eye Movement (REM) sleep behavior disorder, and sleep-disordered breathing, have all been associated with an increased risk of neurodegeneration, and are an independent risk for cognitive decline and dementia in PD [1]. Periodic limb movements of sleep and restless legs syndrome are also very common in PD. In conjunction, sleep abnormalities, in particular REM sleep without atonia, are an important bio-marker for disease and disease progression [3]. Indeed, the etiology of impaired sleep in PD is multifactorial and is likely an interaction between internal and external factors, such as primary sleep disorders [4], primary neurodegeneration [5–7], medication side effects [5–8], environmental conditions, and genetic factors [9]. Each factor can contribute alone or as a modifier, resulting in variability and poor diagnosis and treatment [8, 9].

Laboratory video polysomnography (vPSG) is the gold-standard for assessing sleep physiology in health and disease. PSG is most useful for diagnosis and treatment of obstructive sleep apnea (OSA), narcolepsy, REM sleep behavior disorder, and non-REM parasomnias [10]. Despite the clear utility of PSG in clinical sleep medicine, high cost and inconvenience have motivated the development of alternative home-based systems [11, 12].

Both the wellness and the clinical markets share an interest in “real-world” and home-based sleep monitoring (HBSM). HBSM can provide longitudinal assessment, avoiding the biggest PSG limitations: The atypical sleeping environment and the single-night snapshot. Measuring multiple nights in one’s own environment can provide insight into sleep dynamics. Such data can prove invaluable for the discovery of new intrinsic sleep patterns, revealing frequency and severity of observed sleep disorders or the impact of various factors (e.g., exercise, food, caffeine, alcohol, medication, and stress). The present paper reviews some of the recent developments in HBSM and provides a ‘road map’ for the implementation of such devices into clinical sleep assessment that can be used to enhance early diagnostics, improve PD treatment and incorporate into clinical trials.

WEARABLE TECHNOLOGIES

NONCONTACT: NEARABLE DEVICES

‘Nearables’ are remote sensors that do not directly contact the body but have been used for assessment of behavior and function. ‘Sleep score’ and ‘Sleep Cycle’ are examples of applications that use a mobile phone built-in accelerometer to monitor movement when the phone is placed near one’s pillow. The applications report on sleep time and sleep phases. Although none of the apps offer raw data and supporting validation studies are not yet available, their affordability and accessibility is a clear advantage.

Several commercially available products use piezoelectric or electrodes (e.g., EarlySense, Emfit Besd sensor) placed under the mattress to estimate respiration, HR and movement [34, 35]. Examination in healthy adults showed moderate agreement (71%) with PSG [34]. The distinction between wake and REM sleep were most often misclassified [34]. A recent study comparing a consumer monitoring device based on ballistocardiography (Beddit Sleep-Tracker) and PSG, showed extremely poor agreement for NREM classifications (kappa=0.095, p<0.001) [35]. These findings suggest poor compatibility with clinical sleep assessment.

Video-based sleep analysis in the home can provide information on sleep efficiency and nocturnal movements. New emerging three-dimensional video analysis shows promise in distinguishing REM sleep behavior disorder (RBD) from other motor activities during sleep, as examined in a PSG lab [36]. However, the utility of such an approach should be further explored in the home, taking into account also ethical concerns about privacy and data security of the recordings.

Radiofrequency devices use changes in radio waves reflection to derive the position of individuals [37, 38]. Such systems provide unlimited data from multiple nights, therefore variance over time can be investigated without compromising privacy. A recent study used both radiofrequency home monitoring (SMHOME), as well as PSG (with both systems) to monitor OSA [37]. The SMHOME classified 92% of cases correctly and showed high agreement with PSG for detecting breathing problems. As expected, night after night, variability was high. Only one study was found using a radiofrequency device in patients with PD (Emerald) [38]. Data on time in bed/per day and number and duration of nightly awakenings showed high variance across and within individuals. More research is needed to fully evaluate the benefits in PD.

BRAIN SIGNAL TECHNOLOGIES

The development of ambulatory technologies capable of monitoring brain activity during sleep longitudinally is critical for advancing sleep science. Systems utilizing movement sensors or autonomic measures are important indirect measures, but they are not sufficient for distinguishing sleep stages that are necessary to diagnose NREM parasomnias or RBD [12, 39].

Several systems incorporating EEG sensors were recently described. Shambroom et al. [40] reported on an automated wireless system based on a headband with three silver-coated fabric sensors. Mikkelsen et al. [41] used ear electrodes to demonstrate automatic sleep EEG classification. Recent work [42] explored the accuracy of the Dreem headband, a dry EEG device in detecting sleep stages. Accuracy was overall high (83.5±6.4%) and comparable to that of experts scoring PSG (86.4±8.0%) [42]. However, the device does not record EOG or EMG, lowering its precision in detecting, for example, REM sleep without atonia.

A promising approach towards ambulatory electrophysiology is flexible electrode arrays. In particular, electrodes printed on soft substrates are marked by their conformity with the skin, are lightweight, ease of placement on the skin, and user comfort. The X-trodes home PSG system [43] is a wireless wearable system which provides a sleep-specific electrode array including two surface EMG sensors on the chin, two EOG electrodes positioned in the proximity of the right eye, and four forehead EEG electrodes placed on the forehead. The system was recently tested in both the laboratory and home setting, showing high accuracy compared to video recording EEG assessment (89– 92%) [43], providing a potentially suitable home-based PSG over multiple nights. However, this should be further explored in patients with PD.

DISCUSSION AND FUTURE DIRECTION

Understanding the link between PD and sleep goes well beyond academic curiosity. If poor sleep quality is a cause and an early indication for neural and motor decline in PD, it is critically important to provide patients, and those that belong to risk groups, with timely information about their sleep quality to initiate treatment or life-style changes. There is still a debate whether sleep disturbances are primary or secondary to PD pathology. Nevertheless, it is important to understand whether their severity is associated with disease progression and whether behavioral modification or therapeutic adjustment can improve a patient’s quality of life and potentially impact disease progression. Furthermore, additional detailed knowledge on sleep and sleep architecture in PD, from multiple nights in the person’s natural environment, can contribute to revealing new biomarkers.

Despite the availability of some devices, those are not validated against the current gold-standard and are based on small studies on healthy adults. The impact of the disease on the measurements may be dramatic negating proper use. Moreover, many of the systems evaluate a specific physiological function (i.e., movement, HR, RR). Such data have merit for specific evaluation such as OSA, hypokinesia or sleep interruptions, but does not provide the full scope of an uninterrupted night’s sleep. Medical validity, standardization and regulation are key to the adoption of digital tools into clinical practice. Possible steps for such implementation are described in Fig. 1. The first stage is concerned with system engineering and validation. A HBSM must accommodate several critical requirements: it must collect medically meaningful data of the highest quality and reliability. Monitoring sleep must take place in a minimally obtrusive manner, enabling subjects to use it routinely without affecting their sleep patterns. A home-based system has to be also easy to operate, otherwise adoption will be limited and will not help resolve the missing data challenge. This first stage must also focus on improving the fidelity of the collected data (i.e., reducing noise sources and artifacts), and the introduction of automated data analysis. The development of real time and cloud-based analysis would expand the clinical utility. With such automation, physicians could obtain a sleep report before meeting the patient.

OPEN IN VIEWER

Fig. 1

Roadmap for sleep staging at home for PD Care.

A HBSM has to be carefully and rigorously validated against the gold standard. Although PSG has limitations, it is imperative to understand whether and under which circumstances HBSM can be trusted and how to interpret collected data. It is important to remember that multifaceted configurations with numerous sensors attached to multiple body locations are useful for research purposes but are unlikely to be used in large clinical trials due to relatively high costs and increased patient burden. Clearly, there is a trade-off between maximizing data power and minimizing the effort involved in obtaining it. Nevertheless, data obtained in the home should encompass as many and as similar outputs as the gold standard (e.g., HR, RR, EEG, and movement).

Once a technology has achieved these steps, the exact manner by which it can affect PD care has to be investigated. Most of what we know about sleep in PD is based on patient self-reports, therefore the validity of what we know about frequency and severity is limited. The next stage is therefore to revisit existing studies, focusing on sleep staging as a tool for helping PD patients. In particular, longitudinal research may help identify new bio markers associated with sleep (Fig.1.2). This step should also focus on characterizing disease progression and severity. Next, sleep mapping of PD patients may help identify sleep disorders and monitor possible treatment, medication efficacy and behavioral factors (Fig.1.3). Addressing regulation requirements and standardization is critical for future clinical adaptation and inclusion into clinical trials and clinical practice (Fig.1.4). Only then, HBSM can be used as a standard tool for routine monitoring and medication control to overall impact patient quality of life (Fig.1.5).

Digital technology helps shifting healthcare from reactive to preventive and predictive care. Within this shift, there is a growing demand to make sleep assessment possible using home-based systems. Recent developments offer new and exciting opportunities, but there is still a long process to ensure clinical use. The recent global situation, under the new COVID-19 reality, further highlights the dire need for a shift towards home-based data collection and telemedicine.